TickerGuard
Buy Day today: Neutral (48) Mixed market breadth · no major macro event
KZIA

Kazia Therapeutics Ltd

Healthcare · Biotechnology

9.60$ +0.3% vs. previous close Closing price · As of: Sep 28, 2026

Ownership

Ownership Structure

Who owns Kazia Therapeutics Ltd (KZIA)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 82.2% of the shares are freely tradable; institutional investors hold 30.8%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 30.8%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 19.8%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 82.2%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 5.8%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 11Mio.

Largest Shareholders

Institutions

Institutions KZIA
Name Stake (%) Shares Change (%) Date
Bleichroeder LP 2.57 400,000 +0.0 03/31/2026
Stonepine Capital Management Llc 2.22 345,179 -25.0 03/31/2026
Point72 Asset Management, L.P. 1.29 200,000 +0.0 03/31/2026
Balyasny Asset Management LLC 1.24 193,114 +0.0 03/31/2026
F.L.Putnam Investment Management 0.92 142,469 +0.0 03/31/2026
Millennium Management LLC 0.65 101,376 +0.0 06/30/2026
Dauntless Investment Group, LLC 0.51 79,832 +7,983,100.0 03/31/2026
Cooperman Leon G 0.32 50,000 +0.0 06/30/2026
Westside Investment Management, Inc. 0.31 47,585 -5.6 06/30/2026

Funds

Funds KZIA
Name Stake (%) Shares Change (%) Date
Exemplar Growth and Income Ser FD 0.93 143,946 -12.2 08/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?